Abstract: The present disclosure provides methods and systems for sequencing proteins. One or more methods disclosed herein may use linkers having an amino acid-reactive group and an additional reactive moiety that may be used to couple a polymerizable molecule. The linker may couple to a polymerizable molecule and an amino acid of a peptide and a capture moiety via the polymerizable molecule, followed by cleavage of the amino acid from the peptide. Further processing and analysis may be conducted using, for example, nanopores or nanogaps.

Abstract: “The present disclosure provides methods and systems for sequencing proteins. One or more methods disclosed herein may use linkers having an amino acid-reactive group and an additional reactive moiety that may be used to couple a polymerizable molecule. The linker may couple to a polymerizable molecule and an amino acid of a peptide and a capture moiety via the polymerizable molecule, followed by cleavage of the amino acid from the peptide. Further processing and analysis may be conducted using, for example, nanopores or nanogaps.

Abstract: A liquid chromatograph includes: a liquid meter that measures a liquid amount of a mobile phase stored in one or more mobile phase containers; and a notification unit that notifies an operator of the liquid amount of the mobile phase in each of the one or more mobile phase containers measured by the liquid meter. According to such a liquid chromatograph, when the operator replenishes the mobile phase to the mobile phase container, it is not necessary to visually measure the liquid amount of the mobile phase or manually input the value to the control device, so that it is possible to reduce the workload of the operator regarding the liquid amount management of the mobile phase.

Abstract: Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.

Abstract: Cells are described that are useful in rapid, sensitive, and accurate cell-based assays for enzyme activity, particularly for enzyme activities associated with botulinum toxins. Such cell expresses a construct that includes an anchor region, a cleavage site, and a reporting region having two or more identical reporter peptides. Enzymatic activity at the cleavage site releases the reporter region into the cytosol of the cell, where multiple degradation events occur. The observed change in the signal is proportional to the enzymatic activity.

Abstract: Disclosed herein are compositions and methods for removing interfering substances from biological samples, biochemical assays, or reagents used in biological samples using porous liposomes that capture and in some instances enrich said interfering substances within the liposomes.

Abstract: Methods are described for measuring the amount of C peptide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying C peptide in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.

Abstract: Disclosed are an identifying method and an identifying system for a centrifuge rotor. The identifying method for a centrifuge rotor is based on a centrifuge rotor identifying system which includes a code disk with a plurality of pairs of magnetic poles, a Hall sensor and a controlling device. The method includes the following steps: according to a predetermined code rule, detecting the duration of each level signal generated from the Hall sensor; according to the total number of windows of the code disk and the duration of each level signal, determining the preliminary code; according to the predetermined code rule, determining the code starter; and based on the code starter, ordering the preliminary code to the rotor final code.

Abstract: The present disclosure provides a method for accurately measuring post-translational modifications in proteins such as antibodies. In particular, the method pertains to the use of heavy isotopic standards to generate a calibration curve to allow for accurate quantitation of a modified peptide. The method may be used to accurately quantify C-terminal truncation in antibodies using mass spectrometry.

Abstract: Method of identifying host-cell proteins in a sample matrix are provided.

Abstract: A test device includes a specimen having a circular cross section that accommodates a test target, a specimen holding part that holds a plurality of the specimens in a row, light emitting elements in which light is incident on two adjacent specimens among the plurality of specimens, a first light guide path 46 that guides light emitted by the light emitting elements, and a second light guide path that is formed to have a smaller diameter than a diameter of the first light guide path and that guides the light emitted by the light emitting elements from the first light guide path to the specimen.

Abstract: Disclosed is a system, a kit, a use and an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The system and method are based on the insight to apply a clustering technique to a reference set of patient data, and then further discriminating the sets of bio markers to be applied. The clusters are determined on the basis of the biomarkers Hepatocyte Growth Factor (HGF), Matrix metalloproteinase 8 (MMP8), and Matrix metalloproteinase 9 (MMP9). The actual classification of the patient is done on the basis of the measurement of the concentrations of either of two sets of biomarkers. For one cluster these are Interleukin-1? (IL1?), Interleukin-6 (IL6), and Collagen Telopeptide. For the other cluster, these are HGF and metallopeptidase inhibitor 1 (TIMP1).

Abstract: Recombinant nucleic acids encoding reporting constructs for characterizing botulinum neurotoxin protease activity and cells that incorporate such recombinant nucleic acids and that are suitable for use in cell-based assays for the neurotoxin are provided. The encoded reporting constructs are a pair of recombinant hybrid proteins that act in concert. The reporting constructs are a pair of recombinant hybrid proteins that act in concert, and that include a botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.

Abstract: Systems and methods of in vivo hydroxyl radical protein foot-printing are presented. These teachings may be used to, for example, study three-dimensional protein structure or bio-kinetics. Radical Dosimetry including an optional intrinsic standard is used on isolated intact cells. Real-time feedback based on an internal standard provides comparability between different experiments and in vivo analysis results in data that is representative of actual biological conditions.

Abstract: Flash Photo-Oxidation Device and Higher Order Structural Analysis is employed for higher order structural analysis of biomolecules. Biomolecular higher order structure (HOS) results from the confounded superimposition of a biomolecule's secondary, tertiary, and quaternary structure and defines the manner in which a biomolecule presents itself and interacts with other biomolecules in living systems. A rapidly growing class of therapeutic drugs, known as biotherapeutics, comprises a variety of proteins, whose therapeutic properties are inherently linked and dependent upon their HOS. As such, HOS analysis of biotherapeutics is an important analytical requirement in the biopharmaceutical industry.

Abstract: A horseshoe crab Factor C protein having activity of Factor C, wherein the horseshoe crab is selected from Tachypleus tridentatus, Limulus polyphemus, and Carcinoscorpius rotundicauda, and wherein the horseshoe crab Factor C protein is produced through being recombinantly expressed from a Chinese Hamster Ovary (CHO) DG44 cell or HEK cell.

Abstract: Disclosed herein is one or more subtilisin variants, nucleic acids encoding same, and compositions and methods related to the production and uses thereof, including one or more subtilisin variants that has improved stability and/or soil removal compared to one or more reference subtilisin.

Abstract: The present invention relates to, in part, methods of improved healthcare in female subjects that, for example, rely on menstrual fluid sampling for applying selection biomarkers.

Abstract: A sample support body for ionization of a sample, including: a substrate having a first surface, a second surface on a side opposite to the first surface, and a plurality of through-holes opening on each of the first surface and the second surface; a conductive layer provided on the first surface; and a matrix crystal layer provided on at least one of the conductive layer and the second surface, in which the matrix crystal layer is formed of a plurality of matrix crystal grains so as to include a gap communicating the plurality of through-holes with an outside.

Abstract: A pyrogenicity test method and assay of endotoxins allows for rapid and ultrahigh sensitivity testing of parenteral pharmaceuticals or medical devices that contact blood or cerebrospinal fluid by employing a Limulus Amoebocyte Lysate (LAL) assay monitored with a photonic-crystal biosensor. The photonic-crystal biosensor is capable of determining the presence of endotoxins in a test sample by detecting shifts in the resonant condition of an open microcavity affected by the changes in the refractive index of the analyte solutions used.

Abstract: Described herein are methods for quickly measuring properties of grain kernels. The methods allow for a quick, qualitative assessment of high amylose content in the grain kernel. The methods described herein allow for the assessment of high amylose content in wheat in either a laboratory setting or in the field with a minimum of equipment required. The results of these methods may be used to determine if high amylose kernels have been contaminated with normal or low amylose kernels.

Abstract: The present disclosure relates to a method for preparing NK cells and an application thereof in treatment of a cancer. The present disclosure provides a pharmaceutical composition prepared from NK cells and a monoclonal antibody of CD105, which can be used for the treatment of colorectal cancer and has a good application prospect.

Abstract: The present disclosure provides electrophoretic systems, methods and compositions for spatial analysis, which can serve to magnify or demagnify spatial resolution of analytes of interest that are captured using electrophoresis. Some implementations can use a diverging or converging electric field in an electrophoretic capture system. Such a divergent or convergent electric field, as opposed to a parallel electric field, can be generated by, for example, utilizing different sizes of electrodes associated with or imbedded in substrates. Also provided herein are electrophoretic systems, methods and compositions for spatial analysis, which can serve to selectively migrate one or more analytes from a region of interest in the biological sample for capture using electrophoresis.

Abstract: Methods are provided for identifying an agent that directly modulates a Bcl-2-associated x-protein (BAX) by promoting or disrupting dimerization of the BAX. Agents that directly modulate BAX by affecting dimerization are also provided.

Abstract: Compositions of the inventive concept provide a therapeutic protein with less than 2% contamination by the therapeutic protein in denatured form. Such compositions provide enhanced specific activity and improved stability on storage and/or in serum than corresponding therapeutic protein preparations resulting from conventional isolation methods.

Abstract: This disclosure relates to methods of determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and methods of evaluating a subject for having a tauopathy, the methods comprising, in part, determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and comparing the amount of the tau PTMs associated with one or more tau peptide fragments with one or more reference levels for the tau peptide fragments, thereby determining whether a subject has a tauopathy.

Abstract: A system for personalized depression disorder treatment is disclosed herein. The system includes a server configured to communicate with existing healthcare resources and to receive patient data corresponding to a patient, the server including an analytics module. The system further includes a first database configured to store empirical patient outcomes, and further configured to communicate with the analytics module. Additionally, the system includes a user device having a graphical user interface (GUI) configured to communicate with the server and to display at least one output generated by the analytics module. The analytics module is configured to determine at least one of a personalized depression treatment and a personalized depression state prediction based on the empirical patient outcomes and the patient data.

Abstract: The disclosed technology provides a computational prediction modeling comprising a novel algorithm for prediction of glycosylation or to optimize biopharmaceutical production of proteins of therapeutic relevance. The model of the disclosed technology can be used to predict glycosylation changes based solely on the stating glycoprofiles in any host cells and known or suggested rules on enzyme specificity. Applications of the invention model are also provided.

Abstract: The presently disclosed subject matter provides devices and methods for sample extraction from a swab during biological sample processing. In particular embodiments, the devices and methods are configured for use in conjunction with microfluidic devices for sample processing.

Abstract: A composition for detecting an analyte in a blood sample includes: a coloring reagent; an oxidoreductase; and a refractive index adjuster.

Abstract: Disclosed are a method for destroying cellular mechanical homeostasis and the use thereof, especially disclosed is a method for destroying cellular mechanical homeostasis by using a Myosin inhibitor thereby leading to cell softening and reduction of fibrosis in tissues and organs. Also disclosed are a method for promoting regeneration and repair of tissues and organs and the use thereof. The Myosin inhibitor can destroy the homeostasis of the cellular mechanical stress system, reduce the rigidity of tissues and organs in a pathological state, and stimulate stress and regeneration reactions similar to those in the regeneration processes in lower organisms; and can use the characteristics to greatly inhibit fibrosis during the organ damage and to promote the regeneration and repair of tissues and organs, and meanwhile can use stress response to greatly improve the ability of cellular genetic repair. The Myosin inhibitor is preferably (?)-Blebbistatin, or a derivative thereof (?)-Blebbistatin O-Benzoate.

Abstract: Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.

Abstract: The present invention relates to the field of biochemistry, more particularly to proteomics, more particularly to protein sequencing, even more particularly to single molecule peptide sequencing. The invention discloses methods for single molecule protein sequencing and/or amino acid identification using cleavage inducing agents which are not specific for one particular amino acid, cleave polypeptides step by step from the N-terminus onwards and provide information on the identity of the cleaved amino acids based on the reaction kinetics.

Abstract: This discloses that compounds of Formula 1 may be used as antifibrotics because they inhibit type 1 collagen production. In particular, this discloses a pharmaceutical composition containing one or more compounds of Formula 1 and methods of using compounds of Formula 1 in fibrosis treatment and inhibiting type 1 collagen synthesis.

Abstract: Method, device, and system for identifying a model-based time dependent light scattering signature that includes receiving an experimental time dependent light scattering signature comprising experimental data descriptive of an average molecular weight of protein components in a solution over time. The method further includes identifying an Ansatz for evaluating the experimental time dependent light scattering signature, the Ansatz being an initial model-based time dependent light scattering signature, the initial model-based time dependent light scattering signature identifying at least one key variable. The method also includes adjusting the at least one key variable in the initial model-based time dependent light scattering signature until a final model-based time dependent light scattering signature is identified. In some instances, the final model-based time dependent light scattering signature identifies at least one protein aggregation mechanism.

Abstract: A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

Abstract: An adjustable aerosol delivery device includes an active liquid container, a carrier liquid container, a piezo disc mounted with a flexible gasket relative to the carrier liquid container, an oscillator configured to generate an ultrasonic wave that causes the piezo disc to oscillate and transmit the oscillations through the carrier liquid to the active liquid to cause at least a portion of the active liquid to become an aerosol, a bushing fixed relative to the carrier liquid container via a fixing portion that conforms to and mates with an entire perimeter of a fixing section of the bushing, and a fastener extending through the piezo disc housing and into the bushing. The fastener is configured to be loosened or tightened to manipulate a compression of the gasket to adjust a particle size of the aerosol. A pull force of the bushing is greater than a counter force of the gasket.

Abstract: Provided herein are methods for determining presence of a target enzyme in a tissue section that include delivering a plurality of probes to a tissue section, where a probe of the plurality of probes comprises a capture agent that comprises a substrate for the target enzyme in the tissue section, and where the capture agent is conjugated to an oligonucleotide.

Abstract: A system includes a camera configured to generate image data and a computing device in electronic communication with the camera. The computing device includes at least one processor and is configured to receive, from the camera, one or more images representative of a location. The computing device is further configured to apply a trained classifier to the one or more images to classify the location into one of at least two risk categories, wherein the classification is based on a likelihood of a subject performing a target behavior based on presence of the subject in the location. The computing device is additionally configured to issue a risk alert responsive to the trained classifier classifying the location into a high-risk category.

Abstract: A bottle includes a body, a cap mounted to a cap neck of the body. The cap has an outer peripheral portion which is provided with a protrusion. Around the cap, there is provided a position indicator indicating whether the cap is at a correctly closed position, based on the positional relationship between the protrusion and the position indicator.

Abstract: A method for detecting a food spoilage microbe in a food sample comprising contacting a food sample with a peptide substrate, comprising a fluorescent agent having an emission wavelength of 650-900 nm, a non-fluorescent agent having an absorption wavelength of 650-900 nm, for quenching said emission of said first fluorescent agent, and a cleavage site located between said fluorescent agent and said non-fluorescent agent, b) monitoring the fluorescence of the sample containing the peptide substrate in step a), wherein an increase in fluorescence is indicative for the presence of food spoilage microbes.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.

Abstract: A method of calibrating a device for measuring the concentration of creatinine in a sample including one or more enzyme modulators, the method comprising: determining sensitivities of the device for each of two or more calibration solutions, wherein each calibration solution has a different amount of enzyme modulator; determining a degree of modulation for each of the two or more calibration solutions; determining a degree of modulation for a sample to be measured; and calculating the sensitivity of the device for the sample, wherein said calculating comprises modifying the sensitivity of one of the two or more calibration solutions by a function comprising the determined degrees of modulation.

Abstract: The present invention provides a tool which exhibits excellent properties in the quantification of autophagy activity. A unimolecular FRET probe of the present invention includes an acceptor consisting of a fluorescent protein to be enzymatically degraded inside a lysosome or a vacuole; and a donor having an amino acid sequence having a sequence identity of 95% or more with respect to an amino acid sequence represented by SEQ ID NO: 1.

Abstract: Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. In some embodiments, the disclosure provides anti-plectin-1 antibodies. In some embodiments, the anti-plectin-1 antibodies are conjugated to a targeted moiety (e.g., a therapeutic moiety or a detectable label).

Abstract: A method for rapidly and highly sensitively measuring endotoxin relies on an endotoxin-measuring agent, which includes a factor C derived from Tachypleus tridentatus that does not have His-tag sequence at the C-terminus, a factor B of a horseshoe crab, and a proclotting enzyme of a horseshoe crab. Each of these proteins can be a recombinant protein obtainable by being expressed using a stably expressing cell line of an insect cell as a host.

Abstract: A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.

Abstract: The present disclosure relates to compositions, methods and test devices for determining the presence of active leukocyte cells, for example, by using novel LE and/or HNE substrates in an electrochemical assay.

Abstract: Provided are a pretreatment device capable of starting pretreatment in a simple operation, and an analysis system provided with the pretreatment device. A container holding unit 12 holds pretreatment containers into each of which a sample is injected, at a plurality of holding positions. A pretreatment unit sequentially performs pretreatment by using the pretreatment containers held at the holding positions of the container holding unit 12 in a specific order. A controller configured to receives a setting of the holding position of a pretreatment container to be used first among the plurality of holding positions in the case where a series of pretreatments using the plurality of pretreatment containers is started by the pretreatment unit.

Abstract: A method of preparing a library of tagged nucleic acid fragments including contacting a population of cells directly with a lysis reagent having one or more protease to generate a cell lysate; inactivating the protease to generate an inactivated cell lysate, and applying a transposase and a transposon end composition containing a transferred strand to the inactivated cell lysate under conditions wherein the target nucleic acid and the transposon end composition undergo a transposition reaction.